

## Enrolment in the Clinical Study at Joondalup Health Campus completed ahead of schedule

- **The HeraBEAT clinical Study at Joondalup Health Campus (JHC) has completed enrolment.**
- **The Study, led by Associate Professor Paul Porter, evaluated the usability, acceptability, accuracy, and reliability of HeraMED's proprietary pregnancy monitoring technology.**
- **Data analyses are being finalised and are expected to be published in the coming weeks.**
- **The Study will now be expanded to explore additional applications for HeraBEAT.**

**HeraMED Limited (ASX:HMD)** ("HeraMED" or the "Company"), a medical data & technology company leading the digital transformation of maternity care with its proprietary in-home maternity care platform, is pleased to announce its clinical Study (the "Study"), led by A/Professor Paul Porter at the Joondalup Health Campus in Western Australia, has completed enrolment.

The clinical Study was completed ahead of schedule. The Study began in July 2020, with recruitment of 80 expectant mothers and was designed to evaluate the usability, accuracy, and reliability of the HeraBEAT device; initially in the antenatal clinic and then at home.

The study specifically evaluated:

- Accuracy - completed by a clinician, comparing HeraBEAT to a hospital CTG machine;
- Usability by expectant mothers - evaluating ease of use and user satisfaction at the clinic and at home; and measured by the international medical standard System Usability Scale (SUS); and
- Utility for remote home monitoring - using the HeraBEAT device for recording continuous foetal heart rate (FHR) trace by the mother, electronically transmitted to the antenatal care team for review and consultation. An assessment of the transmission, including data clarity and clinical utility, was made by the clinical team.

The data from the Study are being finalised by the team and the results are expected to be published in the coming weeks.

The researchers, together with the support of JHC has elected to expand the Study, to cover additional case studies, and explore additional applications which could unlock further opportunities for HeraMED.

This Clinical Study represents part of HMD's well-defined strategy of generating clinical validation for its HeraCARE platform, with the aim of establishing it as the standard of care in remote, foetal and maternal wellbeing.

Proving the value of HMD's technology in a clinical setting enables the Company to leverage the results of studies to generate new commercial opportunities, underpinning its long-term commercial objectives.

The onset of COVID-19 has presented a unique opportunity to fast-track the adoption of digital health in maternity care. HMD is well-placed to deliver high-quality, prenatal and postpartum care to improve the safety, efficiency, and cost of maternal healthcare. HMD continues to receive significant interest from prospects from around the world and is well-placed to capitalise on these opportunities.

**CEO and Co-founder Mr David Groberman also added:** "The Study was conducted by an highly experienced clinical and research team that specialises in innovative technology focused on Obstetrics and Paediatrics. We look forward to continuing to work with them to determine the potential for additional applications which may represent further value creation for HMD.

"We anticipate that the data generated from the Study will provide important clinical validation of proprietary technology that we will leverage across our current as well as other markets to generate new opportunities," he said.

For personal use only

This announcement has been authorised by the Board of HeraMED Limited.

-ENDS-

**HeraMED Limited**  
CEO and Co-Founder  
David Groberman  
M: +972 52 6991188  
E: [David@hera-med.com](mailto:David@hera-med.com)

**Company Secretary**  
Jonathan Hart  
T: +61 2 8379 2961  
E: [Jonathan@hera-med.com](mailto:Jonathan@hera-med.com)

**Media Enquiries**  
Melissa Hamilton  
Media & Capital Partners  
M: +61 4 1775 0274  
E: [Melissa.hamilton@mcpartners.com.au](mailto:Melissa.hamilton@mcpartners.com.au)

**About HeraMED Limited (ASX:HMD):**

HeraMED is an innovative medical data & technology company leading the digital transformation of maternity care by revolutionising the pre and postnatal experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data and a digital social networking dashboard.

**About HeraCARE**

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.